Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALTO study of S-1 versus capecitabine in first-line metastatic colorectal cancer
NL-OMON41674Phase 3Active, not recruiting
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Teysuno arm with Capecitabine arm (2 arms). Primary endpoint: Incidence of hand-foot syndrome. Started Jan 2014; status: active, not recruiting.
02
Drugs
tegafurcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON41674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41674.